Catriona Lewis, University of California - Irvine, School of Medicine, 1001 Health Sciences Rd, Irvine, CA 92617, USA,
J Prev Alzheimers Dis. 2022;9(2):286-296. doi: 10.14283/jpad.2022.13.
There is evidence of relationships between behavioral symptoms and increased risk for Alzheimer's Disease and/or Alzheimer's Disease biomarkers. However, the nature of this relationship is currently unknown.
To evaluate the relationship between anxiety and depressive symptoms and amyloid-β deposition in cognitively unimpaired older adults, and to assess mediating effects of either objective or subjective cognitive skills.
Cross-sectional analysis of screening data from participants enrolled in the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease (A4) Study (ClinicalTrials.gov Identifier: NCT02008357).
Data analysis.
4492 cognitively unimpaired adults, age 65-85, enrolled in the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease (A4) Study.
We used linear regression to estimate the associations between amyloid-β standard uptake value ratio (SUVR) and Geriatric Depression Scale (GDS) and State Trait Anxiety Inventory (STAI) scores while adjusting for potential confounding factors as well as for Cognitive Function Index (CFI) or Preclinical Alzheimer's Cognitive Composite (PACC) scores as possible mediational variables.
4399 subjects with complete covariates were included (mean age: 71.3, 59% female), GDS ranged 0-13 (mean: 1.0), and STAI ranged 6-24 (mean: 9.9). Amyloid-β SUVR was modestly associated with STAI; mean STAI score was estimated to be 0.275 points higher (95% CI: 0.038, 0.526; p-value = 0.023) for each 0.5-point increase in cortical amyloid-β SUVR. Subjective cognitive decline (CFI) attenuated the relationship between SUVR and STAI, while objective cognitive function (PACC) did not. No statistically significant relationship between SUVR and GDS was observed (p = 0.326).
In cognitively unimpaired adults with low levels of depression and anxiety, cortical amyloid-β deposition is associated with anxiety but not depressive symptoms. Attenuation of this relationship by subjective cognitive difficulties suggests that anxiety may be partly due to such a perception resulting from cortical amyloid-β deposition.
有证据表明行为症状与阿尔茨海默病和/或阿尔茨海默病生物标志物的风险增加之间存在关系。然而，这种关系的性质目前尚不清楚。
评估认知正常的老年人中焦虑和抑郁症状与淀粉样蛋白-β沉积之间的关系，并评估客观或主观认知技能的中介作用。
来自无症状阿尔茨海默病抗淀粉样蛋白治疗（A4）研究（ClinicalTrials.gov 标识符：NCT02008357）参与者的筛查数据的横断面分析。
数据分析。
4492 名认知正常的成年人，年龄在 65-85 岁之间，参加了无症状阿尔茨海默病抗淀粉样蛋白治疗（A4）研究。
我们使用线性回归来估计淀粉样蛋白-β标准摄取比值（SUVR）与老年抑郁量表（GDS）和状态特质焦虑量表（STAI）评分之间的关联，同时调整潜在的混杂因素，以及认知功能指数（CFI）或临床前阿尔茨海默认知复合评分（PACC）作为可能的中介变量。
纳入了 4399 名具有完整协变量的受试者（平均年龄：71.3，59%为女性），GDS 范围为 0-13（平均：1.0），STAI 范围为 6-24（平均：9.9）。淀粉样蛋白-β SUVR 与 STAI 呈中度相关；皮质淀粉样蛋白-β SUVR 每增加 0.5 个单位，STAI 平均得分估计增加 0.275 分（95%CI：0.038，0.526；p 值=0.023）。主观认知下降（CFI）减弱了 SUVR 与 STAI 之间的关系，而客观认知功能（PACC）则没有。未观察到 SUVR 与 GDS 之间存在统计学显著关系（p=0.326）。
在抑郁和焦虑程度较低的认知正常成年人中，皮质淀粉样蛋白-β沉积与焦虑有关，但与抑郁症状无关。这种关系的减弱表明，焦虑可能部分是由于皮质淀粉样蛋白-β沉积导致的这种感知。
